O6-Methylguanine DNA Methyltransferase (MGMT) Expression by Immunochemistry May Help Predict Response to Streptozotocin-based Chemotherapy in Pancreatic Neuroendocrine Tumours Abstract #1546

Introduction: Streptozotocin (STZ) is an alkylating agent inducing DNA damage mainly repaired by MGMT. STZ-based chemotherapy is the first line treatment of non-resectable well-differentiated PNET. As for temozolomide, tumour MGMT deficiency may predict the efficacy of STZ in PNET.
Aim(s): Assessment of the predictive value of MGMT in a monocentric retrospective cohort of PNET treated with STZ-based chemotherapy.
Materials and methods: All patients with a well-differentiated PNET treated with a STZ-based chemotherapy according to the Moertel scheme between 01/2006 and 02/2014 were selected. Efficacy of the chemotherapy was assessed on CT-scan according to RECIST 1.1 and by PFS. MGMT expression was assessed by immunochemistry with a score (0-300) combining the % of positive cells by the intensity of the staining (0-3).
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr Olivia Hentic
Keywords: MGMT, Streptozotocin, PFS

To read results and conclusion, please login ...

Further abstracts you may be interested in

#475 Methylguanine DNA Methyl Transferase (MGMT) Expression Predicts Response to Temozolamide in Patients with Digestive Neuroendocrine Tumors (NETs)
Introduction: Temozolomide (TEM) is an oral drug with encouraging results in pancreatic NETs (PNETs). MGMT tumor deficiency seems to be correlated with higher treatment efficacy.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Olivia Hentic
Authors: Hentic O, Cros J, Rebours V, Zappa M, ...
#842 O6-Methylguanine DNA Methyltransferase (MGMT) Expression and Ki-67 Index Predict Response to Temozolomide in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumors (WDPNET)
Introduction: Temozolomide (TEM) showed encouraging results in WDPNET. Decreased MGMT expression and methylation of its promoter seems to correlate with better outcome in TEM-treated glioblastomas.
Conference: 11th Annual ENETS Conference (2014)
Category: Biomarkers
Presenting Author: Dr Jerome Cros
Authors: Cros J, Hentic O, Rebours V, Zappa M, ...
#1900 Well-Differentiated G1/G2 Pancreatic NETs Can Evolve Towards G3 Tumors
Introduction: Well-differentiated G1/G2 pancreatic NET (pNET) may evolve towards well-differentiated G3 pNET or carcinoma (pNEC)
Conference: 14th Annual ENETS conference (2017)
Category: Pathology, grading, staging
Presenting Author: Muller Nelly
Authors: Hentic O, Cros J, Rebours V, Zappa M, ...
#1828 5-Fluorouracile Plus Dacarbazine in Metastatic Digestive Neuroendoendocrine Tumors: Efficacy and Potential Biomarkers
Introduction: The 5-fluorouracile (5FU) + dacarbazine (DTIC) combination has been poorly evaluated in NET
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment – Chemotherapy, medical treatment - others
Presenting Author: Dr Louis de Mestier
#1337 O6-Methylguanine DNA Methyltransferase (MGMT) Deficiency and Response to Aranoza-Based Therapy in Patients with Neuroendocrine Tumors
Introduction: Aranoza (3-α-L-arabinopyranosyl-1-methyl-nitrosourea) – nitrosourea derivative, as STZ. O6-methylguanine DNA methyltransferase (MGMT) is an enzyme implicated in chemotherapy resistance to alkylating agents and its low levels are associated with sensitivity to them.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Svetlana Polozkova